Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$11.95
0.423.64%
Last update: Jul 21, 1:38 PM
Evommune Inc Analyst Ratings
EVMNNYSE
Evommune Analyst Ratings and Price Targets | NYSE:EVMN | Benzinga
Evommune Inc has a consensus price target of $41.57 based on the ratings of 10 analysts. The high is $53 issued by Clear Street on March 18, 2026. The low is $26 issued by Morgan Stanley on June 30, 2026. The 3 most-recent analyst ratings were released by Morgan Stanley, HC Wainwright & Co., and Morgan Stanley on June 30, 2026, May 26, 2026, and May 11, 2026, respectively. With an average price target of $43.67 between Morgan Stanley, HC Wainwright & Co., and Morgan Stanley, there's an implied 265.41% upside for Evommune Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Morgan Stanley
RBC Capital
Clear Street
Oppenheimer
Raymond James
1calculated from analyst ratings
Analyst Ratings for Evommune
Loading calendar...
FAQ
What is the target price for Evommune (EVMN) stock?
The latest price target for Evommune (NYSE:EVMN) was reported by Morgan Stanley on June 30, 2026. The analyst firm set a price target for $26.00 expecting EVMN to rise to within 12 months (a possible 117.57% upside). 17 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Evommune (EVMN)?
The latest analyst rating for Evommune (NYSE:EVMN) was provided by Morgan Stanley, and Evommune maintained their overweight rating.
When was the last upgrade for Evommune (EVMN)?
There is no last upgrade for Evommune
When was the last downgrade for Evommune (EVMN)?
The last downgrade for Evommune Inc happened on June 30, 2026 when HC Wainwright & Co. changed their price target from N/A to N/A for Evommune Inc.
When is the next analyst rating going to be posted or updated for Evommune (EVMN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Evommune, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Evommune was filed on June 30, 2026 so you should expect the next rating to be made available sometime around June 30, 2027.
Is the Analyst Rating Evommune (EVMN) correct?
While ratings are subjective and will change, the latest Evommune (EVMN) rating was a maintained with a price target of $55.00 to $26.00. The current price Evommune (EVMN) is trading at is $11.95, which is out of the analyst’s predicted range.
